Damora Therapeutics, Inc.

DMRA · Nasdaq · SIC 2834: Pharmaceutical Preparations
73
SEC Filings

Business Summary

1 Item 1A. Risk Factors 37 Item 1B. Unresolved Staff Comments 72 Item 1C. Cybersecurity 72 Item 2. Properties 73 Item 3. Legal Proceedings 74 Item 4. Mine Safety Disclosures 74 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 75 Item 6. Reserved 75 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 76 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 87 Item 8. F...

Next Earnings

Q2 FY2026 — expected 2026-09-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionDMRAdiscussed_in_filing Cybersecurity
topic_mentionDMRAdiscussed_in_filing Cybersecurity
topic_mentionDMRAdiscussed_in_filing Cybersecurity
topic_mentionDMRAdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-115922EDGAR91K words
2025-03-192024-12-310000950170-25-041981EDGAR—
2024-03-082023-12-310000950170-24-028610EDGAR—
2023-03-092022-12-310000950170-23-006807EDGAR—
2022-02-172021-12-310001564590-22-005569EDGAR—
2021-03-292020-12-310001564590-21-015916EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269426EDGAR21K words
2025-08-052025-06-300000950170-25-102963EDGAR—
2025-05-082025-03-310000950170-25-066884EDGAR—
2024-11-012024-09-300000950170-24-119809EDGAR—
2024-08-122024-06-300000950170-24-095383EDGAR—
2024-04-292024-03-310000950170-24-049808EDGAR—
2023-11-062023-09-300000950170-23-059367EDGAR—
2023-07-312023-06-300000950170-23-035925EDGAR—
2023-04-282023-03-310000950170-23-015461EDGAR—
2022-11-082022-09-300000950170-22-022935EDGAR—
2022-07-292022-06-300000950170-22-013434EDGAR—
2022-04-292022-03-310000950170-22-006612EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001193125-26-118699EDGAR6K words
2026-03-100001193125-26-099404EDGAR—
2026-02-110001193125-26-046817EDGAR—
2026-02-100001193125-26-043741EDGAR—
2026-01-120001193125-26-009812EDGAR—
2026-01-060001193125-26-003490EDGAR—
2025-11-100001193125-25-273342EDGAR—
2025-06-200000950170-25-088168EDGAR—
2024-10-150000950170-24-114481EDGAR—
2024-10-070000950170-24-113091EDGAR—

73 total filings indexed. 45 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001800315
TickerDMRA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 7e55fac3a0525f0bc388768cd21f3d42a8b43283927535790c80b560eb01a763
parent: 32338ac3e4d147dba05386efdf3796cd0451b6aa3c061052b9b82a1e18632723
content hash: d1d215a46742ec143a6ede657151ba473334f22ca0f020f6916e64e24bbfd28f
signed: 2026-04-13T04:44:41.084Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf